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List of abbreviations 
MBD Ultra-Seq: MBD Ultra-Sequencing 
FACS: fluorescence-activated cell sorting 
5mC: 5-methylcytosine 
vmPFC: ventromedial prefrontal cortex 
gDNA: genomic DNA 
UTR: untranslated region 
MBD: methyl CpG binding domain 
DMR: differentially methylated region 
MACS: model-based analysis of Chip-Seq, the enrichment identifier 
RME: region of 5-methylcytosine enrichment (relative to baseline, not necessarily differentially 
methylated) 
LUMA: LUminometric Methylation Assay 
qPCR: quantitative polymerase chain reaction 
RRBS: reduced-representation bisulphite sequencing 
WGBS: whole-genome bisulphite sequencing 
MeDIP: methylated DNA immunopreciptation 
 
 
 
 
 
 
 
 
 
 
Genes, Brain and Behavior (Techniques)   MBD Ultra-Sequencing 
 
 3 
Background 
By regulating the transcriptional output of the genome, experience-dependent changes in DNA 
methylation can exert profound effects on neuronal function and behaviour. A single learning event 
can induce a variety of DNA modifications within the neuronal genome, some of which may be 
common to all individuals experiencing the event, whereas others may occur in a subset of individuals. 
Variations in experience-induced DNA methylation may subsequently confer increased vulnerability or 
resilience to the development of neuropsychiatric disorders. However, the detection of experience-
dependent changes in DNA methylation in the brain has been hindered by the interrogation of 
heterogeneous cell populations, regional differences in epigenetic states, and the use of pooled tissue 
obtained from multiple individuals. 
 
Results  
MBD Ultra-Seq overcomes current limitations on genome-wide epigenetic profiling by incorporating 
fluorescent-activated cell sorting and sample-specific barcoding to examine cell-type specific CpG 
methylation in discrete brain regions of individuals. We demonstrate the value of this method by 
characterising differences in 5-methylcytosine (5mC) in neurons and non-neurons of the ventromedial 
prefrontal cortex of individual adult C57/Bl6 mice, using as little as 50 ng of genomic DNA per sample. 
We find that the neuronal methylome is characterised by greater CpG methylation as well as the 
enrichment of 5mC within intergenic loci. 
 
Conclusion 
MBD Ultra-Seq is a robust method for detecting DNA methylation in neurons derived from discrete 
brain regions of individual animals. This protocol could easily be applied to detect learning- or 
experience-dependent changes in DNA methylation in a variety of behavioural paradigms. 
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Introduction 
Experience-induced changes in DNA methylation are associated with the formation and maintenance 
of memory (Miller et al., 2010, Miller & Sweatt, 2007, Vanyushi.Bf et al., 1974), vulnerability to 
neuropsychiatric disorders following adverse early life experiences (Chen et al., 2012, Labonte et al., 
2012, Murgatroyd et al., 2009, Weaver et al., 2004), as well as the development of addiction (Anier et 
al., 2010, Day et al., 2013, Muschler et al., 2010, Tian et al., 2012) and fear-related anxiety disorders 
(Kang et al., 2013, Labonte et al., 2013). Accordingly, epigenome-wide association studies stand to 
reveal a host of novel biomarkers of susceptibility to psychiatric illness and to shed light on common 
mechanisms of memory formation and maintenance. However, due to technical limitations, genome-
wide investigations of experience-dependent changes in DNA methylation in vivo have predominantly 
examined heterogeneous brain tissues (Day et al., 2013, Grayson et al., 2005, Kang et al., 2013, 
Laufer et al., 2013, Mill et al., 2008, Mizuno et al., 2012, Sabunciyan et al., 2012, Simmons et al., 
2012, Tian et al., 2012), which impedes the discovery of disease- and learning-related changes in 
DNA methylation (Guintivano et al., 2013). 
 
Cellular heterogeneity confounds epigenetic profiling in two ways (Guintivano et al., 2013, Heijmans & 
Mill, 2012, Michels et al., 2013). First, changes in cellular composition within a region can produce 
spurious discoveries of changes in DNA methylation (Guintivano et al., 2013). For example, chronic 
stress induces microglial proliferation in the prefrontal cortex (Hinwood et al., 2012), which could be 
reflected by global changes in DNA methylation if the entire cortex was examined, despite the 
absence of genuine intracellular changes in methylation. Secondly, if the change in DNA methylation 
occurs within a distinct cell population, such as recently activated neurons, even prominent changes in 
5-methylcytosine (5mC) may be imperceptible due to the relative under-abundance of these cells in 
the regional mosaic (Guintivano et al., 2013).  Fortunately, several methods exist for isolating cells of 
interest from tissue, including fluorescence-activated cell sorting (FACS) (Guez-Barber et al., 2012, 
Iwamoto et al., 2011, Jiang et al., 2008, Kozlenkov et al., 2013, Okada et al., 2011, Saxena et al., 
2012), magnet affinity cell sorting, laser-capture microdissection (Vincent et al., 2002) and statistical 
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correction for varying cellular composition (Guintivano et al., 2013). However, the amount of DNA 
yielded following the application of these techniques is often on the order of nanograms and 
insufficient for the preparation of next-generation sequencing libraries that currently call for a 500ng-
1μg of input DNA.  
 
To sequence low amounts of input DNA, tissue from multiple biological replicates may be pooled or 
some form of whole genome amplification employed. However, pooling samples obscures inter-
individual variation in methylation that could govern differences in susceptibility to developing 
neuropsychiatric disorders, and whole genome amplification has the potential to introduce bias and 
artefacts (Aird et al., 2011, Warnecke et al., 1997). Furthermore, many protocols become exceedingly 
labour-intensive and expensive if applied to the large number of samples used in behavioural 
paradigms. Here we describe a novel approach to determine genome-wide CpG methylation in 
neurons derived from discrete brain regions of individual animals by pairing FACS with a modified 
MBD-Seq protocol. We have applied this technique using as little as 50 ng of DNA per animal to 
identify differentially methylated regions (DMRs) within neurons and non-neurons of the ventromedial 
prefrontal cortex (vmPFC) of individual adult C57/Bl6 mice. We find DMRs around several neuron-
specific genes and emphasise the importance of using a cell-type-specific technique, as few neuronal 
DMRs were detected in a heterogeneous population of cells derived from the vmPFC. We conclude 
that MBD Ultra-Seq is a robust and cost-effective method for determining CpG methylation on a 
genome-wide level in neurons and other cell populations in individual animals.  This technique will be 
invaluable for identifying DMRs associated with learning and memory, as well as for interrogating the 
neuronal epigenome in neuropsychiatric disorders. 
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Results 
Neurons exhibit greater 5mC enrichment than non-neurons  
Neurons have a distinct CpG methylation profile compared to non-neurons or whole vmPFC (Figure 
1). On average, in each individual, we identified significantly more regions of 5mC enrichment (RME, 
enriched relative to background) in neurons (178 ± 28 RMEs) than in non-neurons (121 ± 25 RMEs) or 
total vmPFC (128 ± 48 RMEs) (F2,18= 7.72, p<0.01, Tukey’s post hoc test, neurons vs. non-neurons, 
p<0.01, neurons vs. vmPFC, p<0.01, Figure 2). Furthermore, there were significantly more properly 
paired reads aligned in neuronal samples (mean: 20083228 reads) than non-neurons (mean: 
10980756 reads)  (t11 = 2.74, p<0.05), which suggests that this is due to more CpG methylation and 
not a facilitated discovery of peaks in a homogeneous neuronal population. However, only 43 of 113 
significant cell-type-specific DMRs (as identified by Student’s t-test, additional file 1) were 
hypermethylated in neurons. This is consistent with a previous report of global hypomethylation in 
neurons (Iwamoto et al., 2011). We reconcile these observations by proposing that neurons have 
more CpG methylation overall (Kozlenkov et al., 2013, Li et al., 2013, Lister et al., 2013) but are 
hypomethylated in CpG-rich regions that are preferentially examined by the LUMA assay (Iwamoto et 
al., 2011) and the high-stringency MBD pull-down we employed (Karimi et al., 2006, Nair et al., 2011). 
 
CpG DNA methylation is enriched in the 3’UTRs of neurons 
As expected, most cell-type-specific DMRs (neurons vs. non-neurons) were located within intergenic 
regions (Figure 3a); collectively, these regions comprise the majority of the genome. However, after 
normalising for the cumulative length of each region, we found an unexpected enrichment of CpG 
methylation in the 3’untranslated region (UTR) of neurons (Figure 3b). In contrast, there was 
significant enrichment of 5mC in the 5’UTRs of non-neurons (Figure 3b). There is extensive 
lengthening of 3’UTRs in the mammalian brain, particularly in neurons (Miura et al., 2013), which may 
be regulated by differential DNA methylation. For example, methylation of CpG islands in the mouse 
H13 and Herc3/Nap1l5 genes promotes the use of downstream alternative polyadenylation sites that 
result in the production of longer transcripts for these genes (Cowley et al., 2012, Wood et al., 2008). 
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Therefore, hypermethylation of the 3’UTR in neurons may regulate the lengthening of 3’UTRs in the 
mammalian brain, which could in turn affect the stability of these transcripts (Miura et al., 2013). It 
should be noted that each identified peak was used for downstream analysis (for illustration, see 
Figure 4), rather than grouping peaks in close proximity, hence the discrepancy between the average 
number of regions of 5mC enrichment identified in individuals and the total number of cell-type-specific 
DMRs (additional file 2).  
 
Validation of cell-type-specific DMRs 
16 cell-type-specific DMRs were selected for confirmatory analysis by MBD-qPCR (additional file 3, 
additional file 4). Candidate loci varied in statistical significance, in fold difference in methylation 
between cell types, in coverage of the region, and in the number of samples that were initially 
identified as having the RME. A wide range of genomic loci were selected in an attempt to identify the 
characteristics of DMRs that reliably validate. We found that 5X coverage in at least one treatment 
group was necessary for the identification of a cell-type-specific DMR. Of the cell-type-specific DMRs 
with 5X coverage in at least one group, 10 of 12 candidates were validated by MBD-qPCR (see 
Figure 5 for select examples). As expected, we were unable to validate similar DMRs with less than 
5X coverage (4 candidates, see additional file 3). These DMRs were marked by substantial inter-
individual variability, with regions of enrichment identified in only one or two biological replicates. 
Correspondingly, DMRs must be initially identified in at least half (3/6) of the biological replicates in 
order to be validated by MBD-qPCR. Based on our experience, we recommend selecting candidates 
of the following characteristics: p<0.02, fold difference >1.2, mean reads > 5, and present in at least 
half of all biological replicates. A minimum of 5X coverage is key, as the ability to identify differences 
between groups is strongly affected by enrichment levels surrounding the locus, due to the fact that 
greater enrichment results in greater depth of sequencing (Robinson et al., 2010, Trimarchi et al., 
2012).  
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Discussion 
To date, investigation of neuronal DNA methylation has been restricted to candidate loci (Labonte et 
al., 2012, Matrisciano et al., 2013, Nishioka et al., 2013, Schor et al., 2013), reduced representations 
of the genome (Guo et al., 2011, Oh et al., 2013) or a meagre number of samples pooled from a 
number of individuals (Guo et al., 2013, Lister et al., 2013). These methods are not amenable to the 
analysis of changes in DNA methylation in response to learning and other environmental experiences, 
where experiments necessitate the use of discrete brain regions and cell types (i.e. neurons), as well 
as numerous samples. MBD Ultra-Seq is well-suited for such experiments, and the increase in 
resolution afforded by the use of neurons and individuals, as well as the ability to use as little as 50ng 
of input DNA, will facilitate the discovery of changes in DNA methylation related to memory formation 
and maintenance. 
 
The strength of MBD Ultra-Seq derives from several improvements to existing protocols. First, we 
have increased the yield of nuclei from tissue by eliminating the use of a sucrose cushion when 
isolating nuclei (Jiang et al., 2008). Moreover, the FACS procedure is applicable to other cell types 
with distinct nuclear markers (i.e. TBR1 for pyramidal neurons, unpublished observations) or to 
transgenic mice with nuclear reporters. Barcoding individual samples using sample-specific indices 
(Illumina Truseq V2) prior to MBD pull-down also enabled the detection of inter-individual variability in 
DNA methylation from ‘pooled’ samples. Pooling samples during MBD pull-down reduces the 
variability attributed to differences in handling and pull-down efficiency, particularly where low amounts 
of DNA are considered. Sample-specific barcoding was also recently used in the construction of 
reduce-representation bisulphite sequencing (RRBS) libraries (Boyle et al., 2012).  
 
When the size of the genomic region is not considered, we find that the majority of differences in DNA 
methylation between neurons and non-neurons occur within intergenic regions. As most neuronal 
activity-induced changes in DNA methylation are likewise located intergenically (Guo et al., 2011), the 
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use of MBD-based enrichment approaches is preferable to RRBS, which does not provide coverage of 
intergenic regions or 3’UTRs outside CpG islands (Wang et al., 2013).  
 
Limitations 
MBD Ultra-Seq provides one of the few methods for profiling genome-wide methylation in a large 
number of samples; however, it is subject to certain limitations. Firstly, mRNA cannot be extracted 
simultaneously from neurons, and consequently the direct relationship between altered DNA 
methylation and gene expression cannot be explored. There are a handful of protocols for isolating 
whole neurons from adult brains (Guez-Barber et al., 2012, Lobo et al., 2006, Saxena et al., 2012); 
however these suffer from reduced yield (120,000 NeuN+ events from an entire mouse frontal cortex) 
and the RNA obtained may be degraded (unpublished observations).  
 
Secondly, unlike whole-genome bisulphite sequencing (WGBS) (Guo et al., 2013, Lister et al., 2013), 
MBD Ultra-Seq cannot be used to profile non-CpG methylation as MBD 2B/3L binds exclusively to 
methylated cytosines in the CpG dinucleotide context. However, in neurons, CpG methylation 
accounts for 46-75% of all methylated cytosines (Guo et al., 2013, Lister et al., 2013) and exhibits 
greater inter-individual variability than non-CpG methylation (Lister et al., 2013), which may be 
indicative of an increased propensity for experience-induced changes in methylation. Moreover, to 
identify differential methylation, WGBS requires 15-30 fold more coverage of the genome than MBD-
Seq (Stevens et al., 2013) and is consequently unsuited for behavioural paradigms that require a large 
number of animals, and for which individual animal resolution may be required. 
 
Alternatively, MeDIP-Seq can be used to assay non-CpG methylation, and protocols optimised for low 
amounts of DNA and numerous samples have been developed (Taiwo et al., 2012). However, within 
the CpG dinucleotide context, MeDIP suffers from reduced sensitivity and specificity compared to 
MBD, generating a high degree of background ‘noise’ (De Meyer et al., 2013) that may impede the 
detection of differentially methylated regions. Nevertheless, although MeDIP-Seq suffers from 
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additional technical limitations, such as the use of single-stranded DNA, it is a viable alternative for 
those wishing to explore non-CpG methylation. As a final limitation, we find that, although MBD 2B/3L 
is highly efficient at enriching for fragments with 7 or more methylated CpGs (De Meyer et al., 2013), 
CpG-rich regions receive greater coverage, which facilitates the discovery of DMRs in these areas. 
Conclusion 
MBD Ultra-Seq is a novel approach for identifying DNA methylation in neurons and non-neuronal 
populations derived from discrete brain regions of individuals, using as little as 50 ng of DNA. We find 
that the neuronal methylome is unique and that CpG-rich regions are hypomethylated. Differences in 
DNA methylation between neurons and non-neurons are predominantly localised to intergenic regions, 
which emphasises the importance of using genome-wide methods to examine this region of the 
genome. However, when the size of the genomic region is accounted for, the greatest proportionate 
difference in methylation between neurons and non-neurons is in the 3’UTR, which may be related to 
the lengthening of 3’UTRs in the neuronal transcriptome of the mammalian brain. We find that DMRs 
with greater than 5X coverage validate reliably, demonstrating the utility of this method. Overall, MBD 
Ultra-Seq provides a tool that can be used to examine and detect neuronal DNA methylation with 
individual animal resolution in a large number of biological replicates, which should greatly facilitate 
the detection of differential methylation related to learning and neuropsychiatric disorders.  
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Materials and Methods 
Mice 
Adult, male C57/Bl6 mice (9 wk old, 20-25g) were used for all experiments. Mice were housed 4 per 
cage on a 12 hr light:dark cycle (lights on 8 am) in a humidity- and temperature-controlled (22°C) 
vivarium, with rodent chow and water provided ad libitum. Mice were sacrificed by cervical dislocation 
and whole brains were snap frozen on liquid nitrogen and transferred to -80°C storage. All procedures 
were conducted according to protocols and guidelines approved by the University of Queensland 
Animal Ethics Committee.  
 
Dissection of the vmPFC 
vmPFCs were microdissected by Palkovits punch (Palkovits, 1973). Briefly, whole brains were 
imbedded in Tissue-Tek® O.C.T. compound (Sakura Finetek) and 300 μm coronal sections were 
serially cryosectioned from 2.96 mm to 0.26 mm anterior to bregma. The vmPFC was retrieved using 
a chilled brain punch (Stoelting), with punches of diameters 0.75-1.5 mm, pre-selected according to 
the dimensions of the vmPFC in each slice (Franklin & Paxinos, 2008). Isolated regions were placed 
immediately on dry ice and stored at -80°C until further use.  
 
Isolation of neuronal and non-neuronal nuclei 
Individual vmPFCs were dounce-homogenised on ice (Kimble Chase Kontes, A pestle, K885300-
0007) in 1.5 ml of chilled nuclear extraction buffer (Jiang et al., 2008) (0.32 M sucrose, 5 mM CaCl2, 3 
mM Mg(Ac)2, 0.1 mM EDTA, 10 mM Tris-HCl (pH 8), 1mM DTT, 1 X protease inhibitor cocktail, 0.3% 
Triton X-100). Nuclear lysates were filtered through a 40-μM cell strainer (BD Biosciences) to remove 
clumps and centrifuged at 4°C for 7 min at 3000 rpm. The supernatant was aspirated and nuclei were 
gently resuspended in 550 μl of ice-cold 1X PBS. The blocking solution (5% bovine serum albumin, 
10% normal goat serum, 1X PBS) was prepared. The anti-NeuN antibody (1:1200, Millipore) was co-
incubated with the fluorescent secondary antibody (1:1400 Alexa Fluor® 488, Invitrogen) (Table 1, 
scale for number of samples) for 10 min at 4°C on a rotating shaker. 50 μl was retained from each 
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sample and pooled for a secondary antibody-only control. Respective stains were added to the 
nuclear solution and incubated for 1 hr at 4°C in a dark room (see Table 1 for staining proportions). 
Prior to FACS, the immunolabelled nuclei were centrifuged at 4°C for 7 min at 3000rpm and gently 
resuspended on ice in ice-cold 1X PBS. 1 μl of DAPI (Invitrogen) was added to the secondary-only 
control to identify nuclei vs. debris. A BD FACSAria II (BD Biosciences) was used to sort nuclei. Prior 
to sorting, 10,000 events from the secondary-only control were used to gate events on the basis of 
their size, granularity and DAPI fluorescence (FITC) to isolate nuclei from debris (Figure 6a). From the 
selected nuclear population, we also established non-specific labelling by Alexa488 (Figure 6b). Prior 
to the sorting of each NeuN-stained sample, 10,000 events were examined to verify the position of the 
gates, as a distinct population of NeuN-positive events is easily recognisable (Figure 6c). On average 
the NeuN-positive population accounted for approximately 60% of the population, or ~80,000 events 
(Figure 6).  
 
DNA extraction 
Nuclei were lysed overnight at 55°C in lysis buffer (100 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.2% SDS, 
200 mM NaCl, 300 μg/ml proteinase K) (Gu et al., 2011). An equal volume of 
phenol:cholorform:isoamyl alcohol (25:24:1, Invitrogen) was added to each sample and mixed by 
vortexing for 2 min. Samples were centrifuged at 14000g for 5 min at room temperature and the 
supernatant was carefully isolated and transferred to a new tube. 2.5 sample volumes of ice-cold 
100% ethanol, 1 μl of glycogen (20mg/ml) and NaCl (final concentration 250 mM) were added to each 
sample. DNA was precipitated for 4 hr at -30°C. Following precipitation, DNA was centrifuged at 
15000 rpm for 30 min at 4°C. Pellets were washed with ice-cold 70% ethanol and subject to further 
centrifugation (10 min, 15000 rpm, 4°C). Ethanol was removed and the pellets were dried by vacuum 
centrifugation at 45°C, then resuspended in 75 μl of ultrapure H2O overnight. To maximise recovery, 
we recommend heating the solution to 37°C in a thermomixer for at least 30 min to overnight. 
Quantification of DNA was performed by Qubit dsDNA HS assay (Invitrogen). We have found that 
spectrophotometry (ie. Nanodrop is unreliable at low amounts of DNA and can result in as much as a 
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7-fold overestimation of the quantity of DNA due to residual phenol contamination. Qubit is robust in 
the presence of phenol and salt contamination and provides reliable quantification. 70,000 events yield 
approximately 400 ng of genomic DNA. 
 
Library preparation 
DNA fragmentation and concentration 
DNA was randomly sheared by sonication (Covaris S2) to create fragments of approximately 300 bp in 
length. For each sample, 50 ng of DNA was resuspended in 130 μl of ultrapure H2O, transferred to 
microTUBEs (Covaris) and sonicated with the following settings: bath temperature: 4°C, duty: 10%, 
intensity: 6, cycle/burst: 100, time: 180 seconds. Fragment size was verified by Agilent 2100 
Bioanalyzer DNA High Sensitivity Assay (Figure 7). Although generally robust for varying quantities of 
DNA, sonication of low amounts of DNA requires optimisation on a per lab basis. Following sonication, 
samples were placed in a new microcentrifuge tube and DNA was vacuum concentrated (Eppendorf 
concentrator plus, V-AQ, 45°C) to a final volume 50 μl.   
 
End repair  
Sonication generates fragments with varying 3’ and 5’ overhangs that may also lack a phosphate 
group at the 5’ end, which renders them incompatible with A-tailing and adapter ligation. End repair 
uses a combination of polymerases with 3’ to 5’ exonuclease activity and 5’ to 3’ polymerase activity to 
remove 3’ overhangs and fill in 5’ overhangs respectively, as well as a polynucleotide kinase to add 
the 5’ phosphate group. All of these are contained in the End Repair Mix (Illumina TruSeqTM DNA V2).  
 
The Resuspension Buffer and End Repair Mix were thawed on ice. Samples were transferred to 200 
μl thin-walled DNase/RNase-free PCR tubes (Axygen), and 10 μl of Resuspension Buffer and 40 μl of 
End Repair Mix were added to each sample of fragmented DNA. Samples were mixed thoroughly by 
gentle pipetting and incubated in a thermal cycler (Bio-Rad) for 30 min at 30°C (lid 100°C). After 
incubation, all samples were spun briefly and transferred to 1.7 ml low-bind microcentrifuge tubes 
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(Maxymum Recovery®, Axygen). 160 μl of AMPure XP beads (1.6:1 beads:sample ratio) was added to 
each sample and DNA was purified as prescribed in the Illumina® V2 TruSeq sample preparation 
guide. We recommend using 1.7 ml microcentrifuge tubes and a DynaMag (Invitrogen) or similar 
strength magnet to facilitate handling. Samples were eluted in 17.5 μl of Resuspension Buffer (vortex 
2 min, incubate at room temperature for 30 min, place on magnetic stand for 5 min) and 15 μl of 
supernatant from each sample was transferred to new DNase/RNase-free PCR tubes for A-tailing.  
 
A-tailing 
The addition of an overhanging dA allows the ligation of the adapters, which carry a complementary 
overhanging dT. 15 μl of end-repaired DNA was mixed with 2.5 μl of Resuspension Buffer and 12.5ul 
of A-tailing Mix by gentle pipetting and incubated at 37°C for 30 min in a pre-heated thermal cycler (lid 
100°C, temperature 37°C). Troubleshooting note: poor A-tailing may cause inefficient adapter ligation. 
The addition of fresh dATP may be helpful in resolving this issue. 
 
Adapter ligation 
The addition of adapters with sample-specific barcodes prior to MBD pull-down allows multiple 
samples to be pooled for a robust pull-down, while retaining sequence information pertaining to 
individual animals. The dilution of adapters for low-input samples is key to avoiding adapter dimers 
that would be sequenced and reduce the coverage of the samples being sequenced.  
 
Adapters were thawed and diluted (1:40) in Resuspension Buffer (we recommend optimising this 
dilution for specific quantities of DNA and confirming the presence or absence of adapter dimers by 
Bioanalyzer). 2.5 μl of Resuspension Buffer, 2.5 μl of ligation buffer and 2.5 μl of the designated 
diluted adapter were added to individual samples and mixed thoroughly by gentle pipetting. All the 
samples were incubated at 30° C for 10 min in a pre-heated thermal cycler. After incubation, 5 μl of 
Stop Ligation Buffer was added to each sample and mixed by pipetting. After the ligation, samples 
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were purified using AMPure XP beads in a 1:1 v/v ratio according to TruSeq V2 guidelines. Ligated 
DNA was eluted in 67 μl of ultrapure H2O.  
 
We detected some adapter dimers by Bioanalyzer and therefore repeated purification with AMPure XP 
beads in a 1:1 ratio, eluting in 67 μl of ultrapure H2O and retaining 65 μl of eluate in a new low-bind 
tube. We confirmed by Bioanalyzer that the amount of adapter dimers was negligible in all samples. A 
1:1 beads/sample ratio may remove a greater number of small fragments compared to the standard 
1.6:1 ratio and this eliminates the need for gel-based size selection.    
 
Checking ligation efficiency 
We determined that the percentage of remaining DNA that was well-ligated by employing the Qubit 
dsDNA HS assay for total DNA quantification, and the SYBR Fast Illumina Library Quantification Kit 
(Kapa Biosystems) to determine the amount of well-ligated DNA in each sample.  Each sample was 
diluted 1:1000 in Library Dilution Buffer prior to use of the Library Quantification Kit, according to the 
manufacturer’s instructions.  
 
Once the size-adjusted concentration of ligated sample in pM was determined, we converted to ng/ml 
using the following formula: 
   ng/ml = (concentration in pM * molecular weight) 
       106 
 Molecular weight = (average length of fragment + adapter * 607.4) + 157.9 
 
We then determined how many ng of well-ligated DNA was present in each sample as a percentage of 
the amount (ng) from Qubit. Typically 50%-60% of fragments were ligated.  
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Pooling and MBD pull-down 
Within each treatment group we pooled 12.5 ng of well-ligated DNA from each biological replicate 
(n=8) for a total of 100 ng in a final volume of 10 μl. We found that it is preferable to pool an equal 
number of animals from each treatment group in each pull-down, to account for differences in MBD 
pull-down efficiency. To facilitate handling, we recommend using sterile 1.7 ml microcentrifuge tubes 
and the DynaMag magnetic stand (Invitrogen) in lieu of the items provided. In cases of prolonged 
storage, it is often best to validate the kit using the included controls prior to use. MBD pull-downs 
(Methylcollector Ultra, Active Motif) were performed as per the manufacturer’s directions, under high 
salt (high stringency) binding conditions. The captured methylated DNA was eluted in 100 μl of 
complete elution buffer. The methyl-enriched fraction was then purified using AMPure XP beads (1.6:1 
ration, beads:sample) and the enriched sample was eluted in 20 μl of Resuspension Buffer.  
 
Amplification 
Following MBD pull-down, 10 cycles of PCR were used to amplify well-ligated methylated DNA. Each 
pool was amplified independently. 20 μl of each sample was transferred into DNase/RNase-free PCR 
tubes and 5 μl of primer cocktail and 25 μl of PCR master mix was added to the sample. PCR was 
performed by initially denaturing for 30 sec at 98°C, followed by 10 cycles of denaturation at 98°C for 
10 sec, 30 sec of annealing at 60°C and 30 sec of elongating at 72°C, then a final 5 min at 72°C, with 
the lid at 100°C for the duration of thermocycling. PCR products were purified using a 1:1 ratio of 
AMPure XP beads as previously described, and eluted in 32.5 μl of Resuspension Buffer. 30 μl of 
eluate was transferred to 0.6 ml low-bind tubes (Maxymum Recovery, Axygen).  
 
Final QC and sequencing  
The final concentration of the PCR-enriched libraries was determined by qPCR against a reference 
library of known cluster density using the Library Quantification Kit (Kapa Biosystems) and Stratagene 
Mx3000P qPCR instrument (Agilent Technologies). The distribution of library fragment size was 
determined using a Bioanalyzer with a High Sensitivity DNA chip (Agilent Technologies). Each final 
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library was adjusted to 8 μM and loaded into one lane of a HiSeq v.3 flow cell (Illumina) following 
cluster generation on the Illumina c-Bot instrument and paired-end (101 bp) sequencing was 
performed using a HiSeq 2000 (Illumina) according to standard manufacturer’s instructions. 
 
Bioinformatics 
High-throughput DNA sequencing 
Paired-end (PE) libraries were sequenced using the Illumina HiSeq2000 sequencing platform with the 
read length of 101bp*2, and the following image processing was performed using the standard 
Illumina Genome Analyzer software and pipelines developed in house. CASAVA software (v1.8.2) was 
used to demultiplex the samples. 
 
Aligning short reads to reference genome  
PE reads were aligned to the reference genome of mouse (mm9) using BWA (v0.6.2) (Li & Durbin, 
2009). Samtools (v0.1.17) (Li et al., 2009) was then used to convert “.sam” files to “.bam” files, sort 
and index the “.bam” files, and remove duplicate reads.  If the same library was sequenced in different 
Illumina runs or lanes, we merged these “.bam” files using Samtools before the step in which 
duplicates were removed. Reads with low mapping quality (Q<20) or that did not align to the reference 
genome were excluded from the downstream peak calling analysis.  
 
Calling peaks 
MACS (v1.4.2) (Zhang et al., 2008) was used to call peaks for each sample with the parameter setting 
“-f BAM --keep-dup=all --nomodel --shiftsize 100 -g mm -p 1e-5--bdg”. All peak summits identified by 
MACS were then collected to get a full list of potential methylation sites. Custom PERL script was 
applied to parse the number of fragments (hereafter referred to as counts) that covered the peak 
summit in each sample. Here fragments refer to DNA fragments in the library that was used for 
sequencing. Thus, each pair of properly aligned PE reads represents one fragment. The total counts 
in each sample were normalised to 10 million, after which the normalised counts for each summit were 
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compared between conditions using two-sided Student's t-Test. Peaks with p-value less than 0.05 and 
the mean of normalised counts in at least one group larger than 5 were considered as differentially 
methylated peaks between conditions. Peak summits located within 600bp were grouped together and 
treated as the same peak using a custom PERL script. The analysis pipeline “Differentially Methylated 
Sites Analyzer (DMSA)” is shown in additional file 5 and all PERL scripts used in DMSA can be 
downloaded from https://github.com/Qiongyi/DMSA/. 
 
Candidate DMR selection 
We did not apply multiple testing corrections, choosing instead to attempt validation of a number of 
DMRs with varying characteristics in order to determine a criterion of real peaks vs. false positives as 
others have done (Li et al., 2013). We took note of the p-value and fold change between groups as 
well as the read coverage, as others recommend 5X coverage for identifying true DMRs (Trimarchi et 
al., 2012).  
 
A 300 bp region surrounding the peak summit of each candidate DMR (n=16) was retrieved using 
UCSC’s genome browser (mm9), and primers (additional file 6) were designed (Primer3) to amplify a 
120-200 bp amplicons overlapping the peak summit. Primer specificity was tested using the NCBI 
blastn suite and optimised using 1 ng/μl sonicated genomic DNA (gDNA), in 10 μl reactions (5 μl 
2XSybr, 1 μl primers (forward + reverse, 10 μM), 2 μl gDNA, 1 μl upH20). 
 
Validation by MBD-qPCR 
To provide both biological and technical validation we generated another cohort of neuronal and non-
neuronal gDNA and performed MBD pull-downs (Methylcollector Ultra, Active Motif) on individual 
animals according to the manufacturer’s directions. Briefly we fragmented 300 ng of gDNA by 
sonication and retained 14 μl as the input to control for the amount of DNA lost during sonication and 
to verify the fragment size using the Bioanalyzer. The remaining DNA was vacuum concentrated to a 
volume of 10 μl prior to MBD pull-down (high salt conditions). The methyl binding reaction was 
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incubated overnight at 4°C. DNA was purified by phenol chloroform extraction and EtOH precipitation 
for 4 hr at -30°C. Methyl-enriched DNA was resuspended in 60 μl of ultrapure H2O and incubated at 
37°C for 3 hr to maximise dissolution. Both input (in a final volume of 80 μl) and methyl-enriched DNA 
(in 60 μl) were stored at -30°C in low-bind tubes (Maxymum recovery, Axygen). qPCR was performed 
in duplicate using a Rotor Gene Q (Qiagen), and replicated if there was any uncertainty. Relative 
enrichment was calculated by normalising to input, then using the delta-delta ct method with the 
NeuN- group set as the control. 
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Figures 
Figure 1. Neurons have distinct CpG DNA methylation compared to non-neurons or bulk 
vmPFC. For each grouped differentially methylated region (see figure 4), the number of 
biological replicates displaying significant 5mC enrichment (as detected by MACS) was 
considered. White indicates that none of the samples (n=6-8/group) showed significant 
enrichment; red indicates that all samples had significant enrichment (displayed as ratio of all 
samples in the group).  
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Figure 2. Neurons display greater CpG methylation than non-neurons or bulk vmPFC. On 
average more regions of 5mC enrichment are identified in neurons (178 ± 28) than in non-
neurons (121 ± 25) or bulk vmPFC (128 ± 48), F2,18= 7.72, p<0.01, Tukey’s post hoc test, 
neurons vs. non-neurons, **p<0.01, neurons vs. vmPFC,**p<0.01.   
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Figure 3. Distribution of the genomic locations of the regions of 5mC enrichment.  
a) When the number of peaks is not normalised for the length of the genomic region over 50% 
of regions of 5mC enrichment are found in the intergenic region, as this region is substantially 
longer than all others. b) When the number of peaks is normalised for the relative length of the 
region, the neuronal genome has a pronounced enrichment of 5mC in 3’UTRs of genes. 
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Figure 4. Individual regions of enrichment (S1-S4) vs. a grouped region of 5mC 
enrichment. All individual regions of 5mC enrichment (S1-S4) were used in downstream 
analysis, although these may occur within one broad region of 5mC enrichment (grouped 
region of 5mC enrichment). Using all regions for analysis is preferable as it avoids equally 
weighting DMRs that are only defined by one or two biological replicates.  
 
                                      
 
 
 
 
 
 
 
 
 
 
 
 
S2 S3 S4 S1 
Grouped region of 5mC  
enrichment 
Individual peaks of 5mC 
enrichment 
Genes, Brain and Behavior (Techniques)   MBD Ultra-Sequencing 
 
 30 
Figure 5. Candidate cell-type-specific DMRs. Sequencing results (table) are derived from the 
average of all individual peaks within the grouped DMR. The plot is indicative of the normalised 
reads surrounding the locus, while the graph shows the relative enrichment as determined by 
MBD-qPCR.  
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Figure 6. Isolation of the neuronal and non-neuronal population by FACS.  
a) The population of nuclei (green and purple) was gated based on size (FCS-A), cell 
granularity (SSC-A) and fluorescence (DAPI, not shown). b) A secondary-only control was used 
to gate NeuN negative samples. c) Neurons (green) were identified using anti-NeuN pre-
conjugated to a fluorescent secondary antibody (Alexa 488). Approximately 80,000 events were 
identified, constituting ~60% of all events.   
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Figure 7. Quantification of the size of DNA fragments following sonication. After 
sonication, fragment size was verified using using a Bioanalyzer with a High Sensitivity DNA 
chip (Agilent Technologies). The majority of fragments were ~300 bp in length.  
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Tables 
 
Table 1. Nuclear staining of neuronal and non-neuronal samples. Staining solution in the 
proportion that is added to 500 μl of nuclei to identify NeuN+ and NeuN- nuclei. A secondary 
only control is used to account for background fluorescence.  
 
Reagent Anti-NeuN 
 (μl) 
Alexa488 
 (μl) 
Blocking 
buffer (μl) 
1 X PBS 
(μl) 
Nuclear 
solution (μl) 
Staining 
solution 
0.6  
(1:1200)  
0.5  
(1:1400) 
50  150 500 
Secondary 
control 
----- 0.5 50 150 500 
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Additional files 
Additional file 1 – Regions of differential DNA methylation between neurons and non-
neurons (grouped). The ‘summits’ of regions of 5mC enrichment in individuals (S1-S4, figure 
4) are often separated by a small distance.  Regions of 5mC enrichment identified in individuals 
that were within 600 bp of each other were grouped together to explore the overall degree of 
methylation of the vmPFC, neurons and non-neurons and the sequencing results are available 
in this file. 
 
Additional file 2 – Regions of differential DNA methylation between neurons and non-
neurons (individual). To avoid failing to detect any cell-type-specific differences in DNA 
methylation, we compared methylation in all biological replicates at each region of 5mC 
enrichment (ie. S1-S4 in figure 4) rather than at grouped DMRs. Significant individual regions of 
5mC enrichment are listed in this file.  
 
Additional file 3 – Candidate cell-type-specific DMRs for validation by MBD-qPCR 
MBD Ultra-Seq information for candidate differentially methylated loci for validation (16).  
Position of the peak summit is the median value for the grouped peak summit derived from all 
individual peaks surrounding the loci. The number of samples with peak refers to the number of 
samples initially identified as having the peak by MACS, which remained statistically significant 
(p<0.05) after a Student’s t-test. For example, a region of 5mC enrichment may have been 
identified by MACS in all NeuN- samples (n=7) for Chr 6 ~ 15137969; however the enrichment 
was only significant at one of the 7 peaks identified. 
 
Additional file 4 – MBD Ultra-Seq data for candidate cell-type-specific DMRs. The original 
data are available in this excel file. 
 
Additional file 5 - Differentially Methylated Sites Analyzer (DMSA) analysis pipeline. 
 
Additional file 6 – Primers used for validation of candidate DMRs by MBD-qPCR. List of 
primers used for the validation of candidate DMRs by MBD-qPCR.  
 
 
 
